Exploring the Predictive Ability of Dysfunctional High-Density Lipoprotein for Adverse Outcomes in Emergency Department Patients with Sepsis: A Preliminary Investigation

Background: High density lipoprotein (HDL) can be readily oxidized in inflammatory conditions and exhibit pro-inflammatory and dysfunctional (Dys-HDL) characteristics. We hypothesize that Dys-HDL may predict adverse outcomes and correlate with inflammatory cytokines in sepsis. Methods: Emergency department (ED) patients with sepsis were enrolled. Blood was drawn at enrollment and after 48 h. Dys-HDL, expressed as HDL inflammatory index (HII), and cytokines were measured. Multivariable logistic regression was used to determine the predictive ability of Dys-HDL for adverse outcomes (death, discharge to hospice, or nursing home). Results: Thirty-five patients were included in the study. HII was not significantly different at baseline or 48 h between patients with adverse outcomes versus those without. However, there was a significant difference in change in HII over the first 48 h between those with adverse outcomes (+0.21, 95% CI −0.13 to 0.31) versus those without (−0.11, 95% CI −1 to 0.11) (P = 0.025). Logistic regression revealed increasing HII to be an independent predictor of adverse outcomes (OR 5.2, 95% CI 1.1–25.1 P = 0.040). Of the 24 patents with cytokine measurements at both time points, significant inverse correlations between change in HII and change in GRO (rs = −0.52, P = 0.0088) and monocyte chemotactic protein-1 (rs = −0.61, P = 0.0014) concentrations over 48 h were observed. Conclusion: Increasing Dys-HDL concentrations in the first 48 h of sepsis are associated with an ongoing inflammatory response and adverse clinical outcomes. Early changes in HII may be a potential biomarker in ED patients admitted with sepsis.

[1]  John P. Donnelly,et al.  Cholesterol levels and long-term rates of community-acquired sepsis , 2016, Critical Care.

[2]  S. Brakenridge,et al.  The long-term burden of severe sepsis and septic shock: Sepsis recidivism and organ dysfunction , 2016, The journal of trauma and acute care surgery.

[3]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[4]  Chong-Jen Yu,et al.  Decreased serum level of lipoprotein cholesterol is a poor prognostic factor for patients with severe community-acquired pneumonia that required intensive care unit admission. , 2015, Journal of critical care.

[5]  H. Gupta,et al.  Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A , 2014, Innate immunity.

[6]  G. Norata,et al.  HDL in innate and adaptive immunity. , 2014, Cardiovascular research.

[7]  G. Hough,et al.  Inflammation, high density lipoprotein and endothelium. , 2014, Current medicinal chemistry.

[8]  R. Hotchkiss,et al.  Reactivation of Multiple Viruses in Patients with Sepsis , 2014, PloS one.

[9]  K. Hirata,et al.  Serum myeloperoxidase/paraoxonase 1 ratio as potential indicator of dysfunctional high-density lipoprotein and risk stratification in coronary artery disease. , 2014, Atherosclerosis.

[10]  C. Bonithon-Kopp,et al.  Low Preoperative Cholesterol Level Is a Risk Factor of Sepsis and Poor Clinical Outcome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass* , 2014, Critical care medicine.

[11]  A. Remaley,et al.  Scavenger Receptor BI and High-Density Lipoprotein Regulate Thymocyte Apoptosis in Sepsis , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[12]  S. Hazen,et al.  Effects of Native and Myeloperoxidase-Modified Apolipoprotein A-I on Reverse Cholesterol Transport and Atherosclerosis in Mice , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[13]  N. Brot,et al.  Humans With Atherosclerosis Have Impaired ABCA1 Cholesterol Efflux and Enhanced High-Density Lipoprotein Oxidation by Myeloperoxidase , 2014, Circulation research.

[14]  S. Hazen,et al.  Site-specific Nitration of Apolipoprotein A-I at Tyrosine 166 Is Both Abundant within Human Atherosclerotic Plaque and Dysfunctional* , 2014, The Journal of Biological Chemistry.

[15]  A. Becker,et al.  Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease. , 2013, Atherosclerosis.

[16]  A. Remaley,et al.  Reconstituted HDL for the acute treatment of acute coronary syndrome , 2013, Current opinion in lipidology.

[17]  R. Hotchkiss,et al.  Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy , 2013, Nature Reviews Immunology.

[18]  A. Gaggar,et al.  Anti-Inflammatory Mechanisms of Apolipoprotein A-I Mimetic Peptide in Acute Respiratory Distress Syndrome Secondary to Sepsis , 2013, PloS one.

[19]  A. Daugherty,et al.  High Density Lipoprotein Protects against Polymicrobe-induced Sepsis in Mice* , 2013, The Journal of Biological Chemistry.

[20]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[21]  Kyuseok Kim,et al.  4F, apolipoprotein AI mimetic peptide, attenuates acute lung injury and improves survival in endotoxemic rats , 2012, The journal of trauma and acute care surgery.

[22]  D. Sviridov,et al.  Neutrophil Activation Is Attenuated by High-Density Lipoprotein and Apolipoprotein A-I in In Vitro and In Vivo Models of Inflammation , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[23]  D. Rader,et al.  Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S] , 2011, Journal of Lipid Research.

[24]  D. Sviridov,et al.  Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. , 2009, Journal of the American College of Cardiology.

[25]  D. Sviridov,et al.  High-Density Lipoprotein Reduces the Human Monocyte Inflammatory Response , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[26]  J. Vincent,et al.  Surviving sepsis campaign guidelines , 2006 .

[27]  Pan‐Chyr Yang,et al.  Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis* , 2005, Critical care medicine.

[28]  D. Rader,et al.  Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport , 2005, Current opinion in cardiology.

[29]  Kenneth R Feingold,et al.  Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. , 2004, Journal of lipid research.

[30]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[31]  J. Verhoef,et al.  Lipoprotein metabolism in patients with severe sepsis , 2003, Critical care medicine.

[32]  T. Meinertz,et al.  Endothelial Dysfunction, Oxidative Stress, and Risk of Cardiovascular Events in Patients With Coronary Artery Disease , 2001, Circulation.

[33]  S. Reddy,et al.  A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. , 2001, Journal of lipid research.

[34]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[35]  D. Rader,et al.  patient-oriented and epidemiological research Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients , 2008 .